HomeCompareLYPHF vs O

LYPHF vs O: Dividend Comparison 2026

LYPHF yields 529.73% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LYPHF wins by $317.1K in total portfolio value
10 years
LYPHF
LYPHF
● Live price
529.73%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$351.3K
Annual income
$921.47
Full LYPHF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — LYPHF vs O

📍 LYPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYPHFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYPHF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYPHF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYPHF
Annual income on $10K today (after 15% tax)
$45,027.15/yr
After 10yr DRIP, annual income (after tax)
$783.25/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $3,554.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYPHF + O for your $10,000?

LYPHF: 50%O: 50%
100% O50/50100% LYPHF
Portfolio after 10yr
$192.8K
Annual income
$3,012.11/yr
Blended yield
1.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

LYPHF
No analyst data
Altman Z
1.5
Piotroski
6/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYPHF buys
0
O buys
0
No recent congressional trades found for LYPHF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYPHFO
Forward yield529.73%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.1%
Portfolio after 10y$351.3K$34.2K
Annual income after 10y$921.47$5,102.74
Total dividends collected$211.1K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: LYPHF vs O ($10,000, DRIP)

YearLYPHF PortfolioLYPHF Income/yrO PortfolioO Income/yrGap
1← crossover$37,187$26,486.56$10,818$608.16+$26.4KLYPHF
2$85,815$46,025.42$11,787$741.68+$74.0KLYPHF
3$141,454$49,631.95$12,946$911.00+$128.5KLYPHF
4$189,585$38,229.58$14,345$1,127.94+$175.2KLYPHF
5$226,799$23,942.82$16,056$1,409.05+$210.7KLYPHF
6$256,060$13,384.38$18,171$1,777.83+$237.9KLYPHF
7$281,045$7,061.29$20,820$2,268.21+$260.2KLYPHF
8$304,340$3,621.64$24,188$2,929.90+$280.2KLYPHF
9$327,476$1,832.63$28,533$3,837.11+$298.9KLYPHF
10$351,321$921.47$34,235$5,102.74+$317.1KLYPHF

LYPHF vs O: Complete Analysis 2026

LYPHFStock

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Full LYPHF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this LYPHF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYPHF vs SCHDLYPHF vs JEPILYPHF vs KOLYPHF vs MAINLYPHF vs STAGLYPHF vs ADCLYPHF vs NNNLYPHF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.